TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19357642

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg per day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Inhaled beclometasone dipropionate (200 microg per day)
Number of subjects: 46
Study: 20335624

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10-20 mg/d for 4 to 15 months)
Number of subjects: 3869
Study: 16270384

Group type: EXPERIMENTAL
Intervention: Purple sweet potato leaves (PSPL) diet (daily consumption of 200 g PSPL)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control diet (low polyphenols, with the amount of carotenoids adjusted to the same level as that of PSPL)
Number of subjects: 16
Study: 11875328

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (25-microg and 50-microg E(2) patch)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (100-microg E(2) patch)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50-microg E(2) patch combined with P (300 mg/day) or MPA (5 mg/day))
Number of subjects: 35

Group type: COMPARATOR
Intervention: Transdermal estradiol (E(2)) alone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Transdermal estradiol (E(2)) plus progestogen
Number of subjects: 35
Study: 9661685

Group type: EXPERIMENTAL
Intervention: Symptomatic transfusion
Number of subjects: 84

Group type: COMPARATOR
Intervention: Threshold transfusion
Number of subjects: 84
Study: 8168297

Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 112

Group type: COMPARATOR
Intervention: Debridement surgery
Number of subjects: 112
Study: 2964980

Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg/day)
Number of subjects: 8
Study: 29486338

Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA) 600 mg twice daily
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 27733252

Group type: EXPERIMENTAL
Intervention: DHA 600mg/d
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: EPA 1800mg/d
Number of subjects: 121

Group type: COMPARATOR
Intervention: EPA 600mg/d
Number of subjects: 121

Group type: COMPARATOR
Intervention: Olive oil placebo 6g/d
Number of subjects: 121
Study: 25568533

Group type: EXPERIMENTAL
Intervention: P. oleracea seeds (500 mg) taken two times a day for one month
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (lactose) capsules taken two times a day for one month
Number of subjects: 0
Study: 22150754

Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound monitoring (scanned in ER and regularly at the ward until surgery)
Number of subjects: 281

Group type: COMPARATOR
Intervention: No regular scanning before surgery (control group)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound monitoring
Number of subjects: 281
Study: 20510551

Group type: EXPERIMENTAL
Intervention: diacetylmorphine
Number of subjects: 226

Group type: COMPARATOR
Intervention: oral methadone
Number of subjects: 226
Study: 19041613

Group type: EXPERIMENTAL
Intervention: Brief Pain Inventory Short Form (BPI-SF)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Open-ended pain question
Number of subjects: 106
Study: 16438017

Group type: EXPERIMENTAL
Intervention: Oral 10 mg diazepam in the evening before surgery and 1.5 mg midazolam at least 15 min before surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 12592230

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg per day for 6 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10100957

Group type: EXPERIMENTAL
Intervention: Daily plasmapheresis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Alternately daily plasmapheresis
Number of subjects: 30
Study: 8671180

Group type: EXPERIMENTAL
Intervention: 1 hour sperm-oocyte interaction (group 1)
Number of subjects: 119

Group type: COMPARATOR
Intervention: 16 hours sperm-oocyte interaction (group 2)
Number of subjects: 119
Study: 1671009

Group type: EXPERIMENTAL
Intervention: Nicardipine (1 and 3 micrograms/dl forearm tissue/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diltiazem (0.5 and 1 microgram/dl forearm tissue/min)
Number of subjects: 0
Study: 6407518

Group type: EXPERIMENTAL
Intervention: 30 micrograms levonorgestrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 350 micrograms norethisterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30412450

Group type: EXPERIMENTAL
Intervention: Health care professionals (physicians and psychotherapists)
Number of subjects: 1481

Group type: COMPARATOR
Intervention: Nonprofessionals
Number of subjects: 1481
Study: 29498948

Group type: EXPERIMENTAL
Intervention: Intravenous propofol
Number of subjects: 300

Group type: COMPARATOR
Intervention: Inhalational sevoflurane
Number of subjects: 300
Study: 26791869

Group type: EXPERIMENTAL
Intervention: ch14.18-UTC (17.5 mg/m²/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: ch14.18-NCI (25 mg/m²/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both ch14.18-UTC and ch14.18-NCI
Number of subjects: 28
Study: 25170655

Group type: EXPERIMENTAL
Intervention: Zero-profile device (ZPD) adjacent to a single-level ACDF
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-level ACDF (C4-6)
Number of subjects: 0
Study: 22710014

Group type: EXPERIMENTAL
Intervention: Team-Initiated Problem Solving (TIPS) intervention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Wait-List Control group
Number of subjects: 34
Study: 20564152

Group type: EXPERIMENTAL
Intervention: 3 cycles of ABVD followed by irradiation at 36 Gy to initially involved sites and 24 Gy to adjacent sites, the upper infradiaphragmatic area, and the spleen.
Number of subjects: 390

Group type: COMPARATOR
Intervention: 3 cycles of ABVD followed by irradiation at 40 Gy to initially involved sites and 30 Gy to adjacent sites, the upper infradiaphragmatic area, and the spleen.
Number of subjects: 390

Group type: COMPARATOR
Intervention: Historic control group (HCG) receiving the same chemotherapy regimen and irradiation at doses of 40 Gy and 30 Gy, respectively.
Number of subjects: 390
Study: 16499954

Group type: EXPERIMENTAL
Intervention: Continuous treatment with 2 mg 17beta‐estradiol plus 1 mg norethisterone acetate (n=30)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 60 mg raloxifene (n=24)
Number of subjects: 54
Study: 16249712

Group type: EXPERIMENTAL
Intervention: Adherence intervention (2 clinics)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Safer sex intervention (4 clinics)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Adherence intervention
Number of subjects: 437
Study: 11260443

Group type: EXPERIMENTAL
Intervention: Observer role plays
Number of subjects: 160

Group type: COMPARATOR
Intervention: Interpreter role plays
Number of subjects: 160
Study: 9530972

Group type: EXPERIMENTAL
Intervention: Normosmic participants
Number of subjects: 35

Group type: COMPARATOR
Intervention: Anosmic participants
Number of subjects: 35
Study: 8028515

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg orally)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (2 tablets orally)
Number of subjects: 27
Study: 2574930

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 46
Study: 1059202

Group type: EXPERIMENTAL
Intervention: Maximal concentric strength
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isometric contraction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Eccentric contraction
Number of subjects: 40
Study: 31297658

Group type: EXPERIMENTAL
Intervention: Glass hybrid restorative system (GH) (Equia Forte Fil, GC, Tokyo, Japan)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nano-ceramic composite resin (RBC) (Ceram.X One Universal, Dentsply, DeTrey, Konstanz, Germany)
Number of subjects: 25
Study: 30615896

Group type: EXPERIMENTAL
Intervention: Immediate prescription of glasses (1.00 D less than full cycloplegic hyperopia)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Observation without glasses unless reduced distance visual acuity, reduced stereoacuity, or manifest strabismus
Number of subjects: 130
Study: 28114954

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery in addition to medication
Number of subjects: 238

Group type: COMPARATOR
Intervention: Medical therapy only
Number of subjects: 238
Study: 25790320

Group type: EXPERIMENTAL
Intervention: PVI without fluoroscopy (X‐)
Number of subjects: 80

Group type: COMPARATOR
Intervention: PVI with fluoroscopy (X+)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (X+ and X‐)
Number of subjects: 80
Study: 23003668

Group type: EXPERIMENTAL
Intervention: Customised PDA
Number of subjects: 34

Group type: COMPARATOR
Intervention: Care-as-usual (paper-and-pencil aids)
Number of subjects: 34
Study: 20732688

Group type: EXPERIMENTAL
Intervention: Postnatal dexamethasone (DEX)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 18443821

Group type: EXPERIMENTAL
Intervention: Dividing attention during viewing of novel naturalistic actions (NNAs)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Dividing attention during verbal description of NNAs while performing a secondary task
Number of subjects: 51
Study: 17915494

Group type: EXPERIMENTAL
Intervention: Language intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 116
Study: 15476905

Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride ophthalmic solution 0.2%
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 11778075

Group type: EXPERIMENTAL
Intervention: G-CSF (5 microg/kg subcutaneously until Day 13 after PBPCT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: GM-CSF (5 microg/kg subcutaneously until Day 13 after PBPCT)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Higher CD3+ count recovery
Number of subjects: 71
Study: 9191824

Group type: EXPERIMENTAL
Intervention: Spectra cell separator
Number of subjects: 15

Group type: COMPARATOR
Intervention: MCS-3P cell separator
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both machines
Number of subjects: 15
Study: 8466741

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 10
Study: 3731895

Group type: EXPERIMENTAL
Intervention: Educational program for COAD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Advised of findings only (Control)
Number of subjects: 0
Study: 31658265

Group type: EXPERIMENTAL
Intervention: Sterile males produced from combining the sterile insect technique using radiation with the insect incompatible technique through Wolbachia‐induced incompatibility (SIT/IIT); approximately 100-200 sterile males released weekly in each household for 6 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified); no intervention mentioned.
Number of subjects: 0
Study: 29397189

Group type: EXPERIMENTAL
Intervention: 342 μg IBI‐10090 dexamethasone drug delivery suspension
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: 517 μg IBI‐10090 dexamethasone drug delivery suspension
Number of subjects: 394

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394
Study: 26597138

Group type: EXPERIMENTAL
Intervention: Reappraisal instruction to down-regulate emotional arousal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Event-related potentials (ERPs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral responses
Number of subjects: 0
Study: 24918735

Group type: EXPERIMENTAL
Intervention: Cultured epithelial autografts (JACE) combined with autograft and artificial dermis preparation
Number of subjects: 39

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 39
Study: 22149003

Group type: EXPERIMENTAL
Intervention: Olmesartan (20 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Telmisartan (40 mg/day)
Number of subjects: 24
Study: 19513973

Group type: EXPERIMENTAL
Intervention: Acemetacin (180 mg/day)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Indomethacin (150 mg/day)
Number of subjects: 137
Study: 17489767

Group type: EXPERIMENTAL
Intervention: Fibrinolytics (administered within six hours of first chest symptoms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anticoagulants (administered after optimal time)
Number of subjects: 0
Study: 15195762

Group type: EXPERIMENTAL
Intervention: Dynamic 123I-MIBG SPECT
Number of subjects: 76
Study: 14508326

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (Normal Saline)
Number of subjects: 36
Study: 10576122

Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2 (rIL-2) treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Healthy donors
Number of subjects: 8
Study: 8896528

Group type: EXPERIMENTAL
Intervention: Acellular vaccines
Number of subjects: 2342

Group type: COMPARATOR
Intervention: Control whole cell vaccine
Number of subjects: 2342
Study: 1665490

Group type: EXPERIMENTAL
Intervention: Continuous infusion chemotherapy with doxorubicin and ifosfamide
Number of subjects: 159

Group type: COMPARATOR
Intervention: Intravenous bolus chemotherapy with doxorubicin and ifosfamide
Number of subjects: 159
Study: 6342842

Group type: EXPERIMENTAL
Intervention: sotalol 320 mg once daily
Number of subjects: 1456

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1456
Study: 3083467

Group type: EXPERIMENTAL
Intervention: Behavior change programming delivered by church volunteers on major cardiovascular risk factors (smoking, elevated blood pressure, elevated serum cholesterol, excess weight, and physical inactivity).
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Training special task forces to coordinate efforts within each church.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High levels of professional (paid staff) involvement.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low levels of professional (paid staff) involvement.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Experimental conditions testing the necessity of training special task forces.
Number of subjects: 20
Study: 29739738

Group type: EXPERIMENTAL
Intervention: Real-time counseling via text-chat
Number of subjects: 534

Group type: COMPARATOR
Intervention: No real-time counseling via text-chat
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: 50 days intervention duration
Number of subjects: 534

Group type: COMPARATOR
Intervention: 28 days intervention duration
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: All participants (regardless of intervention)
Number of subjects: 534
Study: 28159671

Group type: EXPERIMENTAL
Intervention: Antibiotic checklist intervention
Number of subjects: 6207
Study: 25771030

Group type: EXPERIMENTAL
Intervention: Traditional cooling (CCP applied to neck, groin, and axillae)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glabrous skin cooling (CCP applied to cheeks, palms, and soles)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 10
Study: 23936981

Group type: EXPERIMENTAL
Intervention: Ferrous fumarate 200 mg/day
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ferrous fumarate 200 mg/day + Ascorbic acid 100 mg/day
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ferrous fumarate 200 mg/day + Ascorbic acid 500 mg/day
Number of subjects: 96
Study: 19959335

Group type: EXPERIMENTAL
Intervention: Bupivacaine (10 cc of 2.5mg/cc with 1:80.000 epinephrine)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (no bupivacaine)
Number of subjects: 200
Study: 18260764

Group type: EXPERIMENTAL
Intervention: 15 microg of vaccine per dose with MF59
Number of subjects: 394

Group type: COMPARATOR
Intervention: 45 microg per dose of vaccine alone
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Vaccine at 15 or 7.5 microg per dose with MF59
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Vaccine at 30, 15, or 7.5 microg per dose with aluminum hydroxide
Number of subjects: 394
Study: 16809802

Group type: EXPERIMENTAL
Intervention: Methoxsalen (40 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cyclosporine (200 mg)
Number of subjects: 12
Study: 14570793

Group type: EXPERIMENTAL
Intervention: Sequential Compression Device (SCD) with thigh-high sleeves at a preset pressure of 50 mm Hg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no SCD)
Number of subjects: 50
Study: 11094856

Group type: EXPERIMENTAL
Intervention: Diet-B (poori and dal-fry)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Diet-A (idly with chutney)
Number of subjects: 8
Study: 8627582

Group type: EXPERIMENTAL
Intervention: 10 mg/kg tirilazad mesylate solution orally with 200 mg ketoconazole once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2 mg/kg i.v. tirilazad mesylate solution with 200 mg ketoconazole once daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: 10 mg/kg tirilazad mesylate solution orally
Number of subjects: 12

Group type: COMPARATOR
Intervention: 2 mg/kg i.v. tirilazad mesylate solution
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 12
Study: 1360277

Group type: EXPERIMENTAL
Intervention: 400 mg/day of azidothymidine (AZT), group A
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 800 mg/day of azidothymidine (AZT), group B
Number of subjects: 28
Study: 3881645

Group type: EXPERIMENTAL
Intervention: Soluble insulin at 10 U/mL
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Soluble insulin at 40 U/mL
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Soluble insulin at 100 U/mL
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bolus SC injection of soluble insulin at 40 U/mL
Number of subjects: 8
Study: 30211719

Group type: EXPERIMENTAL
Intervention: Multisystem balance training (8 weeks)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Upper limbs group (control)
Number of subjects: 84
Study: 29232180

Group type: EXPERIMENTAL
Intervention: ParentNet app
Number of subjects: 161
Study: 26616678

Group type: EXPERIMENTAL
Intervention: Doxycycline (3-week course)
Number of subjects: 31
Study: 25121991

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 581

Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 581
Study: 21928921

Group type: EXPERIMENTAL
Intervention: Feedback indicating progress on egalitarian goals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Feedback indicating failure on egalitarian goals
Number of subjects: 0

Group type: COMPARATOR
Intervention: No feedback on egalitarian goals
Number of subjects: 0
Study: 20483887

Group type: EXPERIMENTAL
Intervention: Quarter dose botulinum toxin A
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Half dose botulinum toxin A
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline injections (Control)
Number of subjects: 30
Study: 17512550

Group type: EXPERIMENTAL
Intervention: 10-min clamp/5-min release regime (group 1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 20-min clamp/10-min release regime (group 2)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 13
Study: 15459914

Group type: EXPERIMENTAL
Intervention: Video-assisted thyroidectomy (VAT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional thyroidectomy
Number of subjects: 20
Study: 11896514

Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (rEpo)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study: 10214018

Group type: EXPERIMENTAL
Intervention: Topical prostaglandin E1 (PGE1) 8 micrograms.g‐1
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Topical prostaglandin E1 (PGE1) 4 micrograms.g‐1
Number of subjects: 4

Group type: COMPARATOR
Intervention: Topical prostaglandin E1 (PGE1) 0 microgram.g‐1, 2 micrograms.g‐1, 4 micrograms.g‐1, and 8 micrograms.g‐1
Number of subjects: 4
Study: 8535682

Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 69
Study: 2712654

Group type: EXPERIMENTAL
Intervention: Half-strength (diluted group) milk
Number of subjects: 69

Group type: COMPARATOR
Intervention: Full strength (undiluted group) milk
Number of subjects: 69
Study: 709214

Group type: EXPERIMENTAL
Intervention: Oral administration of labetalol
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intravenous administration of labetalol
Number of subjects: 17
Study: 31527093

Group type: EXPERIMENTAL
Intervention: CLACfast (≤2 FiO2 adjustments/min)
Number of subjects: 19

Group type: COMPARATOR
Intervention: CLACslow (≤0.3 FiO2 adjustments/min)
Number of subjects: 19

Group type: COMPARATOR
Intervention: RMConly (routine manual control)
Number of subjects: 19
Study: 30346317

Group type: EXPERIMENTAL
Intervention: Defecation Postural Modification Device (DPMD)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No DPMD
Number of subjects: 52
Study: 29424804

Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/d)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 25957010

Group type: EXPERIMENTAL
Intervention: Supervised aerobic interval training (AIT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Supervised continuous moderate exercise training (CMT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Unsupervised control group (CON)
Number of subjects: 33
Study: 24638852

Group type: EXPERIMENTAL
Intervention: Higher nicotine cigarettes
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lower nicotine cigarettes
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All test cigarettes
Number of subjects: 120
Study: 22937145

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 19545338

Group type: EXPERIMENTAL
Intervention: Inducibility of ventricular arrhythmias (VT or VF)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Non-inducibility of ventricular arrhythmias
Number of subjects: 204
Study: 17309377

Group type: EXPERIMENTAL
Intervention: FSN intervention (needles inserted and swayed in the subcutaneous layer 200 times in 2 minutes)
Number of subjects: 47
Study: 15036490

Group type: EXPERIMENTAL
Intervention: peroral estradiol valerate 2 mg/day
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: transdermal estradiol gel containing 1 mg estradiol/day
Number of subjects: 58